Key result
Mitoxantrone treatment decreased the median EDSS score from 4.0 to 3.5 in patients with relapsing-remitting multiple sclerosis, but scores remained stable in secondary progressive and worsened in primary progressive multiple sclerosis.
Why the study?
With increasing availability of new immunomodulatory therapies, there is a need to re-identify clinical variants and stages of multiple sclerosis where mitoxantrone can be most effective.
Does mitoxantrone improve clinical and neuroradiological outcomes in patients with various forms of multiple sclerosis?
Population
100 MS patients (36 RRMS, 36 SPMS, and 28 PPMS)
Comparison
Mitoxantrone efficacy across RRMS, SPMS, and PPMS clinical variants
Design
Retrospective non-randomised observational cohort study
Authors
Loading...
May support mitoxantrone in active relapsing-remitting MS; leaves open its role in progressive forms pending randomized trials.
Observational (n=100)
No
Does mitoxantrone improve clinical and neuroradiological outcomes in patients with various forms of multiple sclerosis?
p-value: p=<0.0001
Mitoxantrone may be a valuable therapeutic option for patients with highly active MS or those on the borderline of relapsing-remitting and secondary progressive MS, but is ineffective in primary progressive MS.
Wawrzyniak et al. (2020) conducted an observational in Multiple sclerosis (n=100). Mitoxantrone vs. Baseline was evaluated on Change in median EDSS score from baseline to end of treatment (p=<0.0001). Mitoxantrone treatment decreased the median EDSS score from 4.0 to 3.5 in patients with relapsing-remitting multiple sclerosis, but scores remained stable in secondary progressive and worsened in primary progressive multiple sclerosis.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: